INKT MiNK Therapeutics
Price Chart
Executive Summary
MiNK Therapeutics (INKT) announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, supported by approximately $1.1 million in non-dilutive funding for IND-enabling development. The deal includes a double-digit percentage share of future commercial revenues and leverages MiNK's allogeneic, off-the-shelf iNKT platform to address high-unmet-need pediatric malignancies.
Key Financial Metrics
Actionable Insight
The non-dilutive funding extends cash runway without equity issuance, while the revenue participation provides upside optionality. Traders should monitor preclinical candidate nomination and future IND filing as key milestones. This collaboration validates MiNK's platform, potentially attracting additional partnerships.
Key Facts
- MiNK Therapeutics secured ~$1.1 million in non-dilutive funding from C-Further to advance PRAME-TCR-iNKT therapy through IND-enabling studies.
- The collaboration includes a meaningful double-digit percentage of downstream commercial revenue, preserving MiNK's long-term value capture.
- Program is non-exclusive, allowing MiNK to retain full rights to its iNKT platform and pursue other indications and partnerships.
- University of Southampton will conduct independent preclinical studies to nominate a lead clinical candidate for first-in-human trials in children.
- This is one of the first programs selected by C-Further, validating the maturity and differentiation of MiNK’s iNKT platform.
Financial Impact
$1.1 million in non-dilutive funding reduces near-term cash burn; double-digit revenue share creates optionality for future monetization.
Risk Factors
- Preclinical development is early-stage; failure to nominate a viable candidate could delay or halt progress.
- Commercial revenue participation is contingent on future product approval and sales, which are highly uncertain.
- Pediatric oncology trials face complex regulatory and enrollment challenges.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252525 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
17d ago
|
Press Release
| $12.20 $12.76 | ▲ +4.59% | ▲ +4.64% | $12.02 (−1.48%) |
|
May 20, 2026
25d ago
|
Press Release
| $10.72 $10.18 | ▼ −5.04% | ▼ −6.27% | $12.02 (+12.13%) |
|
May 15, 2026
4w ago
|
8-K
| $10.72 $10.87 | ▲ +1.40% | ▲ +0.44% | $12.02 (+12.13%) |
|
May 15, 2026
4w ago
|
Press Release
| $10.72 $10.87 | ▲ +1.40% | ▲ +0.44% | $12.02 (+12.13%) |
|
May 14, 2026
4w ago
|
Press Release
| $10.51 $10.94 | ▲ +4.09% | ▲ +4.81% | $12.02 (+14.37%) |
|
May 12, 2026
4w ago
|
Press Release
| $11.41 $10.04 | ▼ −12.01% | ▼ −12.08% | $12.02 (+5.35%) |
|
May 8, 2026
5w ago
|
Press Release
| $10.95 $10.04 | ▼ −8.31% | ▼ −8.23% | $12.02 (+9.77%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $14.21 $10.95 | ▼ −22.94% | ▼ −23.50% | $12.02 (−15.41%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $10.57 $11.47 | ▲ +8.51% | ▲ +4.75% | $12.02 (+13.72%) |
|
Mar 31, 2026
10w ago
|
8-K
| $10.53 $11.15 | ▲ +5.89% | ▲ +1.94% | $12.02 (+14.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access